US2022363743A1PendingUtilityA1

Anti-angpt2 antibodies

Assignee: BOEHRINGER INGELHEIM INTPriority: Jun 27, 2019Filed: Jun 17, 2022Published: Nov 17, 2022
Est. expiryJun 27, 2039(~12.9 yrs left)· nominal 20-yr term from priority
A61K 39/3955C07K 2317/92C07K 2317/565A61P 33/00A61P 13/12C07K 2317/76A61K 2039/505A61K 9/0019A61K 45/06A61P 11/00A61P 9/00C07K 16/22C07K 2317/33Y02A50/30
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to new anti-angiopoietin 2 (ANGPT2) neutralizing antibodies for therapeutic and diagnostic methods and composition using them.

Claims

exact text as granted — not AI-modified
1 - 11 . (canceled) 
     
     
         12 . An isolated polynucleotide encoding a heavy chain variable region amino acid sequence or a light chain variable region, wherein the heavy chain variable region amino acid sequence comprises any of SEQ ID NOs: 3 to 7, SEQ ID NOs: 13 to 17; SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, or SEQ ID NO: 39; a and the light chain variable region amino acid sequence comprises any of SEQ ID NOs: 8 to 12, SEQ ID NOs: 19 to 26, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, or SEQ ID NO: 40.

Join the waitlist — get patent alerts

Track US2022363743A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.